HIV合并COVID-19患者的多中心注册研究:特征、合并症与结局
该多中心注册研究连续纳入2020年4月至7月确诊的286例HIV合并COVID-19患者,主要终点为入住ICU、机械通气或死亡的复合终点。结果显示57.3%住院,16.5%需ICU,总体死亡率9.4%,高龄、慢性肺病、高血压及CD4<200 cells/mm3与不良结局相关。
要点
- HIV合并COVID-19患者住院率57.3%,ICU入住率16.5%,总体死亡率9.4%。
- 高龄、慢性肺病、高血压及CD4<200 cells/mm3与严重结局相关。
- ART方案及HIV病毒抑制状态与预设结局无关联。
核心结论
- HIV合并COVID-19患者中严重临床结局常见,合并症多及CD4细胞计数低者风险更高,尽管HIV病毒已抑制。
研究设计与样本
- 多中心注册研究,连续非随机抽样纳入2020年4月1日至7月1日实验室确诊COVID-19的HIV感染者286例,数据录入REDCap系统。
主要发现
- 286例患者平均年龄51.4岁(标准差14.4),25.9%为女性,75.4%为非洲裔美国人或西班牙裔。
- 94.3%接受抗逆转录病毒治疗,88.7%HIV病毒学抑制,80.8%有合并症。
- SARS-CoV-2阳性后30天内,164例(57.3%)住院,47例(16.5%)需ICU入住。
- 总体死亡率为9.4%(27/286),住院患者中为16.5%(27/164),ICU患者中为51.5%(24/47)。
- 主要复合终点发生于全部患者的17.5%(50/286)和住院患者的30.5%(50/164)。
关键数值与推荐
- 主要终点为入住ICU、机械通气或死亡的复合终点,次要终点为需要住院。
- 高龄、慢性肺病和高血压与严重结局相关;CD4计数<200 cells/mm3与主要和次要终点相关。
- ART方案或缺乏病毒抑制与预设结局无关联。
临床怎么用
- 对HIV合并COVID-19患者应关注高龄、慢性肺病、高血压及低CD4计数等不良预后因素。
- 即使HIV病毒学抑制,CD4<200 cells/mm3仍需警惕严重COVID-19结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People living with human immunodeficiency virus (HIV) may have numerous risk factors for acquiring coronavirus disease 2019 (COVID-19) and developing severe outcomes, but current data are conflicting. METHODS: Health-care providers enrolled consecutively, by nonrandom sampling, people living with HIV (PWH) with lab-confirmed COVID-19, diagnosed at their facilities between 1 April and 1 July 2020. Deidentified data were entered into an electronic Research Electronic Data Capture (REDCap) system. The primary endpoint was a severe outcome, defined as a composite endpoint of intensive care unit (ICU) admission, mechanical ventilation, or death. The secondary outcome was the need for hospitalization. RESULTS: There were 286 patients included; the mean age was 51.4 years (standard deviation, 14.4), 25.9% were female, and 75.4% were African American or Hispanic. Most patients (94.3%) were on antiretroviral therapy, 88.7% had HIV virologic suppression, and 80.8% had comorbidities. Within 30 days of testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 164 (57.3%) patients were hospitalized, and 47 (16.5%) required ICU admission. Mortality rates were 9.4% (27/286) overall, 16.5% (27/164) among those hospitalized, and 51.5% (24/47) among those admitted to an ICU. The primary composite endpoint occurred in 17.5% (50/286) of all patients and 30.5% (50/164) of hospitalized patients. Older age, chronic lung disease, and hypertension were associated with severe outcomes. A lower CD4 count (<200 cells/mm3) was associated with the primary and secondary endpoints. There were no associations between the ART regimen or lack of viral suppression and the predefined outcomes. CONCLUSIONS: Severe clinical outcomes occurred commonly in PWH with COVID-19. The risks for poor outcomes were higher in those with comorbidities and lower CD4 cell counts, despite HIV viral suppression. CLINICAL TRIALS REGISTRATION: NCT04333953.
引用
- Dandachi D, Geiger G, Montgomery MW, et al. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019. Clin Infect Dis. 2021. PMID: 32905581. doi:10.1093/cid/ciaa1339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。